The Senate could vote on Rep. Tom Price's (R-Ga.) nomination for Health and Human Services Secretary as early as the coming week.
Price's nomination has been controversial and drawn strong opposition from Democrats, who say he made a false statement to the Senate Finance Committee about an exclusive deal he was given on a medical stock while in Congress.
However, Republicans have defended Price and say Democrats are just playing politics to try to delay President Trump's nominees.
Price's confirmation is an important step in Republican efforts to dismantle ObamaCare, given that a big part of their plan is executive actions by the administration.
Sens. Ted CruzRafael (Ted) Edward CruzOvernight Health Care — Presented by Carequest — Colin Powell's death highlights risks for immunocompromised The Senate confirmation process is broken — Senate Democrats can fix it Australian politician on Cruz, vaccines: 'We don't need your lectures, thanks mate' MORE (R-Texas) and Bernie SandersBernie SandersBiden says expanding Medicare to include hearing, dental and vision a 'reach' Schumer endorses democratic socialist India Walton in Buffalo mayor's race On The Money — Sussing out what Sinema wants MORE (I-Vt.) will debate ObamaCare on Tuesday night on CNN. There are sure to be some fireworks.
House conservatives, meanwhile, are pushing to have as much of ObamaCare as possible be repealed. They are concerned about talk by some Republicans of "repairing" the law instead of full repeal.
"We committed to the American people to repeal every tax, every mandate, the regulations, and to defund Planned Parenthood," Reps. Mark Meadows (R-N.C.), the chairman of the conservative House Freedom Caucus, and Jim Jordan (R-Ohio), the former chairman, said in a statement Thursday.
On a possibly more bipartisan front, the House Energy and Commerce Committee will consider legislation next week aimed at incentivizing generic drug development and increasing competition.
Chairman Greg Walden (R-Ore.) said the bill will require the Food and Drug Administration to "prioritize, expedite and review generic applications of drug products that are currently in shortage."
Walden's announcement followed a meeting between President Trump and a group of drug company executives at the White House on Tuesday. At the meeting, Trump called on drugmakers to bring prices down.
"President Trump made it clear in the White House meeting I attended with him and Vice President Pence: He wants competition that will bring lower drug prices and that is precisely what this measure will accomplish," Walden said.